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Any delay in adequate antibiotic treatment may compro-
mise the outcome of ventilator-associated pneumonia
(VAP). However, the diagnosis and optimal treatment of
VAP remain a challenge for intensivists. Jung et al. [1]
assessed the potential impact of using results of once-a-
week routine quantitative endotracheal aspirate (EA)
cultures to guide initial antibiotic treatment in a study of
113 episodes of bronchoalveolar lavage-conﬁrmed VAP.
When guided by EA, the initial antibiotic regimen was
adequate in 85% of situations, a proportion signiﬁcantly
superior to that resulting from application of the ATS
guidelines (73%). When clinicians did not have a pre-
VAP EA to guide their treatment (EA not performed
group), only 61% of treatments were adequate, conﬁrm-
ing that routine surveillance cultures may help to improve
the adequacy of empiric antibiotic therapy for VAP.
Respiratory physiotherapy and early mobilisation have
been suggested to both prevent and treat VAP. Patman
et al. [2] performed a prospective, randomised controlled
trial in 144 patients with acquired brain injury (ABI)
on the effect of physiotherapy. This study found that a
regular respiratory physiotherapy regimen including
positioning, manual hyperinﬂation and suctioning repe-
ated six times per day, when provided in addition to
routine medical/nursing care, did not signiﬁcantly reduce
the incidence of VAP, length of MV or ICU/hospital stay
for adults with ABI. Due to the small number of patients
diagnosed with VAP, it was not possible to draw any
conclusions as to whether respiratory physiotherapy has-
tens the recovery from VAP in terms of duration of MV,
length of ICU/hospital stay or clinical variables such as
the daily CPIS score.
Previous studies have established that acquisition of
P. aeruginosa is associated with the administration of
antimicrobial agents devoid of antipseudomonal activity.
In this regard, however, the role of antipseudomonal
agents is less clear. During an intervention study aimed to
compare a mixing versus a cycling strategy of antibiotics
use in the critical care setting, Martinez et al. [3] were able
to gather detailed longitudinal data about exposure to
antibiotics and colonisation by P. aeruginosa. Their
data suggest that quinolones and antipseudomonal ceph-
alosporins may actually prevent the acquisition of
P. aeruginosa, whereas piperacillin-tazobactam and ami-
kacin may enhance it. With respect to the acquisition of
resistance, they found that quinolones and cephalosporins
were rather neutral, whereas all the other agents were
associated with the acquisition of resistance also to other
antibiotics. Interestingly, emergence of resistance never
arose to detectable levels before 3 days of continuous
therapy and combination treatment was not useful for
prevention.
It remains uncertain why immunocompetent patients
with bacterial community-acquired pneumonia (CAP) die,
in spite of adequate antibiotics. In a secondary analysis of
212 patients admitted to 33 ICUs in Spain for CAP, ICU
mortality was 20.7 and 28% [OR 1.49 (0.74–2.98)]
among immunocompetent patients with S. pneumoniae
(n = 122) and non-pneumococci (n = 90), in spite of
initial adequate antibiotic treatment [4]. Multivariable
regression analysis identiﬁed the following variables as
independently associated with mortality: shock (HR
13.03), acute renal failure (HR 4.79) and APACHE II
score higher than 24 (HR 2.22).
To investigate the effect of enteral Synbiotic 2000
FORTE (a mixture of lactic acid bacteria and ﬁbres) on
the incidence of ventilator-associated pneumonia (VAP)
in critically ill patients, 259 enterally fed patients
requiring mechanical ventilation for 48 h or more were
enrolled in a prospective, randomised, double-blind, pla-
cebo-controlled trial [5]. No statistical difference was
demonstrated between groups receiving synbiotic or pla-
cebo in the incidence of VAP (9 and 13%), VAP rate per
1,000 ventilator days (13 and 14.6) or hospital mortality
(27 and 33%). These results are in agreement with two
recent meta-analyses of small heterogeneous populations
of critically ill patients, which also failed to show a
reduction in infectious complications with symbiotic
therapy.
A threshold of C10
4 colony forming unit (CFU) ml
-1
is currently used to deﬁne a positive quantitative culture
result for BAL, and thus to diagnose VAP. Variation of
dilution under a dilution factor of 10 or higher than a
dilution factor of 100 could alter this cutoff, resulting in
an inappropriate interpretation of the microbiological data
and then in overtreating some patients or missing some
episodes of pneumonia. In a study of 127 consecutive
patients who were clinically suspected of having devel-
oped VAP and underwent BAL, Baldesi et al. [6] found
that a misclassiﬁcation of the BAL related to the dilution,
as determined by the urea method, was observed in only
2.1% of the 241 BALs performed for a suspicion of VAP.
Furthermore, this misinterpretation could have led to
underdiagnosing a VAP in only two of the ﬁve cases.
Soluble triggering receptor expressed on myeloid
cells-1 (sTREM-1) has proven to be a good biomarker for
sepsis. For the diagnosis of ventilator-associated pneu-
monia (VAP), however, there have only been a few,
relatively small studies on the role of this receptor. In a
study of 240 BAL ﬂuids obtained from patients with a
clinical suspicion of VAP, the mean concentration of
sTREM-1 was signiﬁcantly higher in the BALF of
patients with conﬁrmed VAP than in that of patients
without conﬁrmed VAP. However, the area under the
receiver-operating characteristic curve was 0.58 (95%
conﬁdence interval 0.50–0.65, P = 0.04), implying that
the sTREM-1 assay used in this study may not be dis-
criminative for VAP [7].
Jiyong et al. [8] presented a meta-analysis evaluating
the clinical feasibility of using TREM-1 in bacterial
197infections. After selection of 13 studies fulﬁlling the pre-
deﬁned criteria of the literature search, they found that
TREM-1 has quite a high sensitivity and speciﬁcity of
bacterial infections, but it is probably not a sufﬁcient
markerinthesubgroupofurinarytract infections.Whether
TREM-1maybeusedtoguideantibiotictherapycannotbe
concluded by present data. Interestingly, similar to pro-
calcitonin (PCT), TREM-1 seems to be able to identify
negative patients in a very reliable manner, much better
thanitsabilitytopredictthepositivediagnosis‘‘infection’’.
Several evidence-based interventions are known to
reduce the incidence of VAP. However, translating evi-
dence-based ﬁndings into consistent delivered care at the
bedside remains a challenge. Hawe et al. [9] evaluated the
effects of introducing a bundle of six evidence-based
interventions to reduce VAP (semirecumbent patient
positioning, oral antisepsis with chlorhexidine, use of sub-
glottic suction/drainage endotracheal tubes, daily sedation
breaks, daily assessment of readiness to wean, and use of
a heat and moisture exchange ﬁlter) via an integrated
‘active implementation program’ involving staff educa-
tion, process and outcome measurement, feedback to staff
and organisational change. Compliance with the VAP
prevention bundle increased after active implementation.
VAP incidence fell signiﬁcantly from 19.2 to 7.5 per
1,000 ventilator days between passive and active periods
and continued falling into the ﬁnal quarter of the time
period described (to 5.5 per 1,000 ventilation days).
Prophylactic antibiotic regimens, such as selective
decontamination of the digestive tract (SDD) and selec-
tive oropharyngeal decontamination (SOD), reduce the
incidence of respiratory tract infections (RTI) in ICU
patients and improve survival. It is unknown how dis-
continuation of these interventions at ICU discharge
changes the patients’ microbial ecology and whether this
inﬂuences their immediate risk of infections. To test the
hypothesis that use of SDD or SOD may increase the
incidence of hospital acquired infection (HAI) after ICU
discharge, de Smet et al. [10] prospectively monitored the
occurrence of HAI during the ﬁrst 14 days after ICU
discharge in all patients transferred to regular wards in
two university hospitals, which were part of a large
multicenter SDD-SOD trial. As compared to standard of
care, the incidences of HAI in general wards tended to be
higher in patients that had received either SDD or SOD
during their ICU stay. The relative risks for developing
HAI in the ﬁrst 14 days after ICU discharge were 1.49
(CI95 0.9–2.47) after SOD and 1.44 (CI95 0.87–2.39) after
SDD. Incidences of surgical site infections (per 100 sur-
gical procedures) were 4 after standard treatment and 11.8
and 8 after SOD and SDD (P = 0.04). Whether discon-
tinuation of the prophylactic regimens may have favoured
the re-emergence of typical hospital pathogens in these
patients remains to be determined.
Patients undergoing major heart surgery (MHS) are a
particularly high-risk population for nosocomial
infections during the postoperative period with a high
incidence and related mortality. To assess the differential
characteristics of patients who develop VAP and to
identify risk factors amenable to intervention in such a
setting, Hortal et al. [11] carried out a prospective study
of VAP in 1,803 patients operated from 2003 to 2006 in
their own institution. Overall, 106 patients developed one
or more episodes of VAP (5.7%, 22.2 episodes per
1,000 days of mechanical ventilation). The independent
risk factors for VAP were: age[70, perioperative trans-
fusions, days of mechanical ventilation, re-intubation,
previous cardiac surgery, emergent surgery and intraop-
erative inotropic support. Because VAP incidence was
particularly high (46%) in patients requiring more than
48 h of MV, innovative preventive measures should be
developed and applied in that ‘‘high-risk’’ population.
Controversies still remain in the management of
hospital acquired pneumonia (HAP) [12] and ventilation-
acquired pneumonia (VAP). Three European Societies,
the European Respiratory Society (ERS), European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) and European Society of Intensive Care
Medicine (ESICM), were interested in producing a doc-
ument on HAP and VAP with a European perspective.
The chairmen of this task force suggested names from
each society to be a member of the panel. They also chose
controversial topics of the ﬁeld and others that were not
covered by the last IDSA/ATS guidelines. Each topic was
assigned to a pair of members to be reviewed and written.
Finally, the panel deﬁned 20 consensual points that were
circulated several times among the members of the panel
until total agreement was reached. A combination of
evidence- and clinical-based medicine was used to reach
these consensuses. This manuscript reviews in depth
several controversial or new topics in HAP and VAP. This
article may be useful for the development of future
guidelines and to stimulate clinical research by lying out
what is currently accepted and what is unknown or con-
troversial. This article was followed by a letter to the
Editor and its rebuttal [13, 14].
To assess the etiologies and outcome of acute respi-
ratory failure (ARF) in HIV-infected patients over the ﬁrst
decade of antiretroviral therapy use, Barbier et al. [15]
reviewed the medical charts of all HIV-infected patients
admitted to their ICU for ARF between 1996 and 2006.
ARF revealed the diagnosis of HIV infection in 43
(29.2%) patients. Causes of ARF were bacterial pneu-
monia (n = 74), Pneumocystis jirovecii pneumonia (PCP,
n = 52), other opportunistic infections (n = 19) and
noninfectious pulmonary disease (n = 33); the distribu-
tion of causes did not change over the 10-year study
period. The 43 patients on antiretroviral therapy more
frequently had bacterial pneumonia and less frequently
had opportunistic infections. Factors independently asso-
ciated with mortality were mechanical ventilation [odds
ratio (OR) = 8.48], vasopressor use (OR, 4.48), time
198from hospital admission to ICU admission (OR, 1.05 per
day) and number of causes (OR, 3.19). HIV-related
variables (CD4 count, viral load and ART) were not
associated with mortality. These data conﬁrm that hos-
pital survival has improved in HIV-infected patients and
depend on the extent of organ dysfunction rather than on
HIV-related characteristics.
Current guidelines for both ventilator-associated
pneumonia and Candida infections suggest that isolation
of Candida spp. in BAL ﬂuid from immunocompetent
patients does not require treatment. However, these rec-
ommendations are contrasted by a survey showing that
24% of intensive care physicians would prescribe anti-
fungal therapy for an immunocompetent, mechanically
ventilated patient with Candida spp. isolated from a tra-
cheal aspirate [16]. In a large retrospective study, in
which all autopsies performed over a 2-year period in an
adult medical ICU were examined at a very high 77%
autopsy rate, no single case of Candida pneumonia was
identiﬁed, even in the patients who had a positive respi-
ratory sample for Candida spp. prior to death. In contrast,
isolation of Candida spp. from respiratory specimens was
very frequent in patients who died with pneumonia,
occurring in 57% [17]. This study indicates that Candida
pneumonia is an extremely rare occurrence in ICU
patients and provides further evidence against the com-
mon use of antifungal therapy triggered by a
microbiology report of Candida isolation from the
respiratory tract.
Interestingly, invasive candidiasis was the topic of a
two-part review by Guery et al [18, 19]. The authors
present the current state of the art of managing invasive
candidiasis and candidemia in adult non-neutropenic
intensive care patients. Epidemiology and diagnosis are
commented on in Part 1 [18]: With Candida albicans as
the most frequent fungal species followed by Candida
glabrata, the diagnosis of invasive candidiasis involves
both clinical and laboratory parameters. One of the main
features is the evaluation of risk factors, such as neutro-
penia, chemotherapy, broad-spectrum antibiotic use and
many more, for infection which will identify patients in
need for pre-emptive or empiric treatment. Unfortunately,
most laboratory or microbiological tests have only a low
sensitivity and speciﬁcity, and the authors conclude that
there is an urgent need for the development of additional
laboratory markers. Part II of that review [19] deals with
the options for treating candidiasis. The most recent
standard drugs are presented, and it is pointed out that the
choice of empiric therapy is dependent on the hemody-
namic status of the patient. Treatment will probably
involve the use of drugs from the echinocandin family if
the patient is unstable. On the other hand, the stable
patient can be treated with azoles as long as there is no
other speciﬁc result from microbiologic testing. Finally,
the authors point to the need for a re-evaluation of current
guidelines.
Infections
Antimicrobial resistance remains important in ICUs, but
the focus of this problem seems to be shifting from the
gram-positive bacteria [such as methicillin-resistant
staphylococcus aureus (MRSA)] to the gram-negative
bacteria and yeasts. A surveillance study in 35 European
ICUs in 2005 demonstrated wide variations in antibiotic
use and proportions of multiresistant bacteria (both gram-
positive and gram-negative). Average proportions of
Escherichia coli and Klebsiella pneumoniae with the
extended-spectrum beta-lactamase (ESBL) phenotype
were 3.9 and 14.3%, respectively [20]. In a before-after
study in a single German ICU, restriction of the use of
third generation cephalosporins (which were reduced
from 178.9 to 68.7 DDD/patient day) was not associated
with a reduction in the prevalence of these multiresistant
bacteria [21]. Another emerging gram-negative pathogen
is Acinetobacter baumanii. In a cohort of 330 trauma
patients, the incidence of A. baumanii infection was 11%,
and these infections were independently correlated with
longer duration of ventilation and trans-skeletal traction,
but not with mortality [22].
It is still difﬁcult to predict the development of inva-
sive candidiasis in ICU patients. Prediction models based
upon either clinical risk factors or Candida-colonisation
parameters performed poorly in a large cohort of Aus-
tralian ICU patients. Integration of these prediction rules
might offer better results, but external validation in dif-
ferent settings is needed ﬁrst [23]. The addition of
procalcitonin measurements might further enhance the
predictive values of such prediction rules, as suggested by
one study of 136 patients [24].
What should be done when a central vascular catheter
(CVC) tip culture grows Candida species, but the patient
has no signs of systemic infection and there is no evi-
dence of candidemia? In a small retrospective study
among 58 non-neutropenic ICU patients antifungal
treatment of such patients was not associated with
improved outcome [25].
Another patient population at risk for fungal infections
is those suffering from recurrent gastrointestinal perfo-
ration, anastomotic leakage or acute necrotising
pancreatitis. In such patients (n = 19) preventive caspo-
fungin therapy, for a median of 16 days (range 4–
46 days), prevented intraabdominal candidiasis in all but
one patient without adverse events requiring discontinu-
ation of therapy [26].
ICU-acquired bacteremia is one of the most important
complications of treatment in the ICU, and is associated
with increased morbidity and mortality, prolonged length
of stay and higher health care costs. Among 343 patients,
of which 63 had diabetes mellitus, in a Greek ICU, 118
developed ICU-acquired bacteremia, and diabetes
patients appeared to have a 1.7-fold risk of this compli-
cation [27]. Among 206 patients with acute liver failure,
19935% developed bacteremia after a median of 10 days.
SIRS scores on admission and the severity of hepatic
encephalopathy were predictive of bacteremia, but not of
mortality, which was only independently predicted
APACHE II score [28]. In contrast, single-stage percu-
taneous dilatational tracheostomy was associated with
bacteremia in 6 of 113 patients (5%), which, according to
the authors, justiﬁes withholding of antibiotic prophylaxis
for this procedure [29].
Surgical treatment is crucial in the management of
necrotising soft tissue infections. In a retrospective study
of 106 patients, of whom 40.6% died during hospitalisa-
tion, time from the ﬁrst signs to diagnosis of less than
72 h and time between diagnosis to surgical treatment
longer than 14 h in patients with septic shock were both
associated with hospital mortality [30].
Hand hygiene is one of the cornerstones of infection
prevention. The old-fashioned practice of washing hands
with water and soap should by now be replaced by
alcohol-based handrubs in all ICUs. In a multicenter study
using self-report questionnaires, use of alcohol-based
handrubs was considered easier and quicker, and was
associated with less hand erythema and itching than
washing hands with water and soap [31].
Sepsis
Biomarkers of inﬂammation and host factors
A number of interesting novel ﬁndings in the areas of
biomarkers of inﬂammation, host factors, diagnostic tests
and pharmacology were published in 2009 in Intensive
Care Medicine.
The need for accurate and reliable biomarkers useable
for the monitoring of patients with sepsis is highlighted by
the high number of publications related to this area.
Indeed, the ‘‘standard’’ C-reactive protein (CRP) can no
longer be considered as a reliable predictor of outcome in
septic patients. In a systematic study carried out over a
14-month period, Silvestre et al. [32] included 158 con-
secutive patients with sepsis, severe sepsis or septic
shock. The ability of CRP (value on the day of diagnosis
of sepsis) to predict survival was lower than the severity
scores (APACHE II, SAPS II) and the Sequential Organ
Failure Assessment (SOFA) score, and in the same range
as white cell count and body temperature.
Hopefully, new insights in the putative pathogenetic
mechanisms of sepsis could help to provide more reliable
biomarkers. For instance, the decreases of serum selenium
concentrations and of glutathione peroxidase (GPx-3)
activity during inﬂammation were studied by Manzanares
et al. [33]. These researchers reported an association
between low admission selenium, low GPx-3 activity and
the occurrence of SIRS (systemic inﬂammatory response
syndrome) in a cohort of 36 patients (without SIRS, with
SIRS and with SIRS and multiple organ dysfunction
syndrome) in comparison to a control group of 23 healthy
volunteers. An association between low selenium and
ICU mortality was also found.
Similarly, Guignant et al. [34] measured in 99 con-
secutive patients the circulating levels of pro-vasopressin
and pro-adrenomedullin, two vasoactive pro-hormones, in
samples drawn the ﬁrst week after the onset of septic
shock. Both pro-hormones were higher in non-survivors
than in survivors, and the combination of both measure-
ments provided an even higher predictive value. These
ﬁndings are consistent with a predominant role of the
cardiovascular alterations of septic shock as a key deter-
minant of outcome. In bacterial meningitis, Berg et al.
[35] assessed the plasma levels of putative vasoactive
mediators, calcitonin-gene related peptide (CGRP),
vasoactive intestinal peptide (VIP) and endothelin-1
(ET-1), and compared these concentrations with a control
group of healthy volunteers. The net cerebral ﬂuxes of
these peptides were also measured in different conditions.
The arterial levels of CGRP were found elevated in
patients with meningitis and decreased in volunteers
during hyperventilation and after endotoxin infusion.
These ﬁndings shed some light on the peculiarities of the
cerebro-vascular alterations associated with acute bacte-
rial meningitis.
Another functional assessment of novel mediators of
sepsis, angiopoietin-2, von Willebrand factor (VWF) and
angiopoietin-1, was reported by van der Heijden et al.
[36]. As these mediators are considered as surrogate
indicators of vascular permeability, a relationship
between their plasma concentrations with ﬂuid balance
and oxygenation parameters was investigated in 50
patients with septic shock. The main ﬁnding was the
positive correlation among angiopoietin-2 and ﬂuid bal-
ance, pulmonary dysfunction and mortality. Both VWF
and angiopoietin-1 were correlated with the magnitude of
pulmonary dysfunction, but not with mortality.
The role of lipoproteins and apolipoproteins was
explored in a study by Barlage et al. [37] in 151 septic
patients. Both lipoproteins and apolipoproteins can play a
role in the altered vascular cell function during inﬂam-
mation. Total cholesterol, high-density-lipoprotein (HDL)
and low-density-lipoprotein (LDL) cholesterol, apolipo-
protein (apo)-AI and apo-B were all lower in non-
survivors than in survivors. Apo-AI and HDL cholesterol
further decreased in non-survivors during the ICU stay.
Logistic regression analysis revealed apo-AI to be an
independent predictor of 30-day mortality. Moreover, a
signiﬁcant inverse correlation was found for apo-AI/
HDL-cholesterol and platelet activation.
The complexity of sepsis is even further ampliﬁed
when considering individual host factors, related to
genetic predisposition, either genotypic or phenotypic.
200Su et al. [38] reported from data sampled in a large
cohort of critically ill patients a signiﬁcantly increased
risk of ARDS in patients bearing a single nucleotide
polymorphism of the Angiopoietin-2 gene, a regulator of
lung inﬂammation and vascular permeability. The asso-
ciation was even stronger when extrapulmonary injuries
were the cause of ARDS.
The functional consequences of the expression of the
heme oxygenase-1 enzyme by monocytes and the arterial
concentration of carbon monoxide were explored by
Takaki et al. [39] in septic and non-septic patients. In
septic patients, indeed, the expression of the heme oxy-
genase enzyme and the arterial blood CO was higher than
in non-septic patients. A positive correlation was found
between the increase in heme oxygenase expression, the
survival rate, the CO concentration and the intensity of
oxidative stress. Such ﬁndings are likely to foster
sophisticated mechanistic hypotheses able to link the
numerous abnormalities reported during sepsis.
Liver dysfunction is another example of severe com-
plication of sepsis, and its pathogenesis is complex. The
risk factors for hypoxic hepatitis, a common cause of
hepatocellular injury, were explored by Fuhrmann et al.
[40]. Low cardiac output and septic shock were the pre-
dominant disorders, and the severity of liver injury was
related to outcome. In the same area, Thomson et al. [41]
evaluated the prevalence, patterns and signiﬁcance of
deranged liver function tests in a group of 263 patients
without prior hepato-biliary disease. Mild liver test
abnormalities were commonly found and were associated
with a increased 30-day mortality, but were not inde-
pendent predictors of mortality after adjustment for
APACHE II score. The severities of ventilatory, renal and
circulatory compromises at admission were associated
with an increased risk of alterations in liver function tests.
Pharmacology and supportive therapies
The metabolism of commonly used drugs can be altered
during critical illness, sometimes leading to unexpected
effects. The kinetics of a commonly used lipid-lowering
drug, atorvastatin, was compared by Kruger et al. [42]i n
critically ill patients and in healthy volunteers. A single
standard oral dose of atorvastatin was given, and different
pharmacokinetic indices were recorded over 24 h. As
compared with the volunteers and with the non-septic
patients, the critically ill patients with sepsis had a
delayed metabolism, implying the persistence of supra-
therapeutic circulating concentrations of the drug up to
20 h after the single dose was given. These ﬁndings are of
major importance for the daily practice, since statins
reduce the plasma levels of cytokines. In an elegant
double-blind controlled randomised trial, Novack et al.
[43] randomised 83 patients with suspected or conﬁrmed
bacterial infection to oral simvastatin or to placebo. The
TNF-alpha and interleukin (IL)-6 levels, analysed in a
subset of 20 in each group, were signiﬁcantly reduced in
the simvastatin group. No difference was observed in other
clinical variables recorded, including mortality. Clearly,
the role of statins in the management of sepsis needs to be
further clariﬁed, including the pharmacokinetic aspects.
The exact role of protein C in the treatment of septic
shock is eagerly debated. Two articles published in
Intensive Care Medicine in 2009 added important contri-
butions to this debate. The ﬁrst report [44] described
unexpected reversal of refractory septic shock with drotr-
ecogin alpha (activated). The 23 patients included in this
observational study had a 100% risk of death, according to
a score based on the response to early continuous veno-
venous hemodiaﬁltration. The actual 28-day mortality rate
of the 23 patients who received drotrecogin alpha was only
39%, associated with a decrease in the magnitude of lactic
acidosis and the dose of norepinephrine required.
In a double-blind randomised placebo-controlled trial,
the safety and efﬁcacy of extended drotrecogin alpha
(activated) (DAA) was evaluated in 64 ICUs in nine
countries. Patients (n = 193) received DAA for a maxi-
mum of 3 days. Yet, extended DAA treatment was not
associated with reductions in day-28 all-cause mortality
and in-hospital mortality, but also not with an increase in
serious adverse events [45].
Heparin used concomitantly with drotrecogin alpha
(activated) (DrotAA) was explored in the XPRESS study,
and no heparin effect on mortality was observed [46]. In
this article, the safety results were explored in more
detail. The patients were randomised 1:1:2 to receive
unfractionated heparin (UFH) (5,000 units twice daily;
n = 511), low-molecular-weight heparin (LMWH) (en-
oxaparin, 40 mg per day; n = 493) or placebo (n = 990)
every 12 h during the DrotAA infusion. The bleeding
events during the DrotAA infusion period (days 0-6) were
higher in the heparin than in the placebo groups (10.8 vs.
8.1%; P = 0.049), but serious bleeding events were
similar (heparin 2.3% vs. placebo 2.5%; P = 0.72), and
central nervous system (CNS) bleeds were rare in both
groups (0.3 vs. 0.3%). Fewer heparin patients experienced
an ischaemic stroke during infusion (0.3 vs. 1.3%;
P = 0.018) and 28-day period (0.5 vs. 1.8%; P = 0.009).
It was concluded that the coadministration of DrotAA
with low-dose heparin in severe sepsis patients did not
increase the incidence of serious bleeding. Fewer
ischaemic strokes in the heparin group suggest heparin
cessation should be avoided during DrotAA infusion.
Crivellari et al. [47] describe the outcome and the
changes in coagulation and inﬂammation of nine con-
secutive patients with severe sepsis who received human
protein C zymogen concentrate after cardiac surgery.
The increase in protein C levels was accompanied by an
early drop in interleukins and near-normalisation of pro-
thrombin time, activated partial thromboplastin time,
antithrombin and thrombin-antithrombin complex levels.
201The 30-day mortality was unexpectedly low as compared
to the prediction.
Diagnostic tests
The daily practice of intensive care medicine implies the
use of routines and of some less frequent diagnostic tests.
Some new insights into the usefulness and the relevance
of some of these common practices were reported in the
Journal last year.
Prat et al. [48] assessed the impact of the implemen-
tation of clinical practice guidelines by a multifaceted
intervention, including a daily routine prescription help
guide developed by a multidisciplinary group and dis-
played at patients’ bedsides, educational sessions and
feedbacks by information on volumes of prescriptions.
The results essentially demonstratea dramatic reductionof
the number of laboratory tests and of chest radiographs,
resulting in signiﬁcant reductions of costs. Importantly,
the mortality rate was unchanged after the implementation
of the guidelines, when the severity of disease was similar.
Briegel et al. [49] evaluated the inter-laboratory and
inter-assay measurements of total cortisol in patients with
septic shock. Samples from the CORTICUS study [Sprung
et al. N Engl J Med 2008] were assayed induplicate, bythe
chemical laboratory of each participating site and by a
central laboratory. In addition, cortisol levels measured by
tandem mass spectrometry were used as a ‘gold standard’
reference method in a subset of samples. The concordance
between tests was highly variable, and the rate of diag-
nosis of corticosteroid insufﬁciency was divergent due to
inter-assay variations in up to 27% of cases.
The effects of another potential confounder of the
diagnosis on adrenal responsiveness, etomidate, was
assessed by Cuthbertson et al. [50] on another subset from
the CORTICUS study. The proportion of non-responders
to corticotropin was signiﬁcantly higher in the 96 patients
who received etomidate within the 72 h prior to inclusion
than in the others. Importantly, etomidate therapy was
associated with a higher 28-day mortality, even after
correction for the severity of illness.
The timing of sample draw could also represent a
potentialconfounder.Incontrasttopreviousbeliefs,Riutta
et al. [51] reported that the diurnal variations of cortisol, as
wellasmelatonin,aremaintainedinintensivecarepatients.
Asampleof40non-septicpatientswasstudied.Theurinary
metabolites of melatonin and the serum cortisol concen-
trations differed between daytime and nights.
Risk factors and outcome
Risk and outcome of critically ill patients remain one of
the most important topics in clinical research. In 2009,
Intensive Care Medicine presented some papers on this
issue: the ﬁrst deals with the impact of obesity on out-
comes after critical illness [52]. Hogue et al. performed a
meta-analysis ﬁnally including 22 studies with more than
88,000 patients. The result was indeed more than sur-
prising: pooled analysis demonstrated no difference in
ICU mortality, but lower hospital mortality for obese and
morbidly obese subjects. Moreover, obesity was not
associated with the time of mechanical ventilation. The
authors conclude that we still do not understand the
altered physiology of obese subjects and that there is a
need for more research activities on this topic. How dif-
ﬁcult it is to apply complex statistical methods when
estimating mortality in clinical trials was nicely shown by
Wolkewitz et al. [53]. Although not easy to understand for
the ‘‘statistical layman’’, the study demonstrated that
some methods like logistic regression have their weak-
nesses, whereas cumulative hazards and probability plots
add important information. This sound and most valuable
piece of work should help to encourage researchers
working in hospital epidemiology to apply adequate sta-
tistical models to complex medical questions that
frequently rise in intensive care medicine. The third paper
touches a really difﬁcult ﬁeld of outcome research: Bus-
chmann et al. [54] investigated complications of
resuscitation attempts requiring invasive iatrogenic
manipulations on the patient, such as intubation or
punctures. The authors differentiate between frequent and
rare complications, and present several examples in dif-
ferent areas of the body. Most importantly, they point on
the fact that these complications may happen even with
adequate execution of the manipulations during resusci-
tation. Hence, it is of utmost importance that clinical
practitioners should know about the relevance and fre-
quency of these injuries to avoid these traumas if possible,
but also to be able to distinguish them from injuries of
other origin.
Acute necrotising pancreatitis is associated with high
morbidity and mortality. Little is known about the long-
term outcome and quality of life in these patients. A
prospective investigation of 31 patients showed a 68%
survival to hospital discharge [55]. One year later patients
showed improvement in their physical function and the
physical component of their QOL, but overall both
functions remained signiﬁcantly reduced compared to the
general population. For example, even walking distance
was signiﬁcantly lower that expected after 12 months,
i.e., 424 versus 503 m (P = 0.014).
Independent of diagnosis leading to ICU admission,
health-related quality of life (HRQoL) prior to admission
appears to be a major determinant of ICU survival and
long-term outcome. A prospective cohort study in 377
patients admitted to the ICU [56] clearly demonstrated
that diminished quality of life assessed by a HRQol score
of [8 is associated with a nearly two-fold risk for
morality 12 months after ICU admission. Reduced life
202quality is also reﬂected by the two other variables found
to be associated with increased mortality, namely pre-ICU
admission hospital length of stay [2 days (OR 2.6) and
high work load assessed by Nine Equivalents of Nursing
Manpower score[30 (OR 3.6).
The SAPS 3 score was introduced as a further
reﬁnement of the widely applied SAPS II score [57] and
was established by including data from 303 ICUs from 52
countries. Application of this score in speciﬁc countries
may show different performances as this is already know
from other severity scores like SAPS II and APACHE II.
A prospective observational study including 28,000
patients from 147 Italian ICUs included in the national
database of the Gruppo italiano per la Valutazione degli
interventi in Terapia Intensiva (GiViTI) [58] found good
discrimination, but poor calibration leading to overesti-
mation of hospital mortality in this large sample of Italian
ICU patients. Though investigations in other countries did
not ﬁnd similar deﬁcits in calibration [59], further adap-
tation of SAPS 3 to speciﬁc national or regional situations
may be necessary.
The Austrian validation and customisation of the
SAPS 3 Admission Score group [60] evaluated the
prognostic performance of the SAPS 3 Admission Score
in a regional cohort and empirically tested the need and
feasibility of regional customisation. Data on a total of
2,060 patients consecutively admitted to 22 intensive care
units in Austria from October 2006 to February 2007 were
collected. The original SAPS 3 Admission score overes-
timated hospital mortality in Austrian intensive care
patients through all strata of the severity of illness. This
was true for both available equations, the general and the
Central and Western Europe equation. For this reason a
customised country-speciﬁc model was developed, using
cross-validation techniques. This model showed excellent
calibration and discrimination in the whole cohort (Hos-
mer-Lemeshow goodness of ﬁt: H = 4.50, P = 0.922;
C = 5.61, P = 0.847, aROC, 0.82) as well as in the
various tested subgroups. Authors concluded that the
SAPS 3 Admission score’s general equation can be seen
as a framework for addressing the issue of outcome pre-
diction in a general ICU adult population. However, for
benchmarking purposes, more differentiated levels of
comparison are needed, and region-speciﬁc or country-
speciﬁc equations seem to be necessary in order to
compare ICUs on a similar level.
Azoulay et al. [61] report on the incidence and char-
acteristics of decisions to forgo life-sustaining therapies
(DFLSTs) in the 282 ICUs that contributed to the SAPS3
database. Data were reviewed in 14,488 patients, and
DFLSTs occurred in 1,239 (8.6%) patients: 677 (54.6%)
had withholding and 562 (45.4%) had withdrawal deci-
sions. Overall hospital mortality was 21% (3,050/14,488),
and 1,105 deaths occurred after DFLSTs. Hospital mor-
tality in patients with DFLSTs ranged from 80.3 to
95.4%. Independent predictors of DFLSTs included 13
variables associated with increased incidence of DFLSTs
and 7 variables associated with decreased incidence of
DFLSTs. Among hospital and ICU-related variables, a
higher number of nurses per bed was associated with
increased incidence of DFLSTs (OR 1.03), while avail-
ability of an emergency department in the same hospital
(OR 0.65), presence of a full time ICU specialist (OR
0.96) and presence of doctors during nights and weekends
(OR 0.72) were associated with a decreased incidence of
DFLSTs. The authors concluded that the ﬁnding that
organisational factors may have signiﬁcant impact on the
incidence of DFLSTs raises crucial questions about the
determinants and deﬁnition of optimal DFLSTs. They
also acknowledged that certain types of cultural variations
are permissible and should not be perceived as incorrect
practices.
Therapeutic advances have improved survival in
patients with myeloma (MM) over the past decade [62].
The authors investigated whether survival has also
improved in critically ill myeloma patients. Consecutive
myeloma patients admitted to a teaching hospital ICU
between 1990 and 2006 were analysed in a retrospective
manner. Three year-of-admission groups (1990–1995,
1996–2001, and 2002–2006) were compared that matched
changes in myeloma treatment (chemotherapy only, stem
cell transplantation and new molecules, respectively). A
total of 196 patients were included. Reasons for ICU
admission and patient characteristics were similar across
groups; however, less use of conventional chemotherapy
and radiotherapy and greater use of steroids were noted in
the more recent periods. Over time, vasopressors and
invasive mechanical ventilation were used decreasingly,
and non-invasive ventilation increasingly, to treat acute
respiratory failure. Hospital mortality decreased from
75% in 1990–1995 to 49% in 1996–2001 and 40% in
2002–2006 (P = 0.0007). Mortality was associated with
poor performance status (OR 2.27, 95% CI 1.04–4.99),
need for mechanical ventilation (OR 4.33, 95% CI 1.86–
10.10), need for vasopressors (OR 2.57, 95% CI: 1.12-
5.86) and admission for an event related to myeloma
progression (OR 2.77, 95% CI 1.13-6.79). ICU admission
within 48 h after hospital admission was associated with
lower mortality (OR 0.28, 95% CI: 0.19-0.89). It was
concluded that hospital mortality has decreased signiﬁ-
cantly over the last 15 years in myeloma patients
admitted to the ICU. Risk factors for death were organ
failure and poor chronic health status. Early ICU admis-
sion was associated with lower mortality, suggesting
opportunities for further improving survival.
Pre-existing organ impairment may be a signiﬁcant
risk factor for intoxication by usually quite harmless fruits
and vegetables. This could be drastically demonstrated in
a study including six cases with chronic renal insufﬁ-
ciencies, who were admitted to the ICU for severe star
fruit intoxication. Two patients did not survive. This
report emphasises the fact that star fruits may not be
203consumed by people with impaired renal function under
any circumstances [63].
Acute renal failure
Deﬁning acute renal failure or acute kidney injury (AKI)
is an important issue in critical care since it was already
demonstrated in the past that the patients’ prognosis is
dependent on that grade of alteration of renal function.
Two large groups consented in the deﬁnition of AKI
criteria: the ﬁrst is the Acute Dialysis Quality Initiative
(ADQI), which developed the RIFLE criteria (RIFLE is
the eponym for the extent of AKI, coming from Risk,
followed by Injury, Failure, Loss of function (for patients
being more than 4 weeks on RRT) and End-stage kidney
disease (ESKD) [64]. The second is the Acute Kidney
Injury Network (AKIN), which developed the AKIN cri-
teria [65]. Joannidis et al. published a very interesting post
hoc analysis using more than 14,000 patient ﬁles from the
SAPS III trial to compare RIFLE and AKIN criteria in
critically ill patients [66]. Both strategies to stratify the
risk of patients with AKI were comparable regarding the
overall survival, showing a stepwise increase of the 30-day
mortality, beginning with the lowest in patients without
AKI, followed by worse outcome in those with AKI
(increasing from risk, injury, to failure and from stage 1, 2
to 3, using RIFLE versus AKIN criteria, respectively).
With regard to a possible misclassiﬁcation, the RIFLE
criteria were more robust than the AKIN criteria. Hence,
this important study will hopefully lead to more accep-
tance and a higher rate of clinical use of well-established
criteria such as RIFLE in critically ill patients.
It is well known that AKI is a frequent complication in
severe sepsis and septic shock [67]. A large retrospective
cohort study using data of 4,532 patients from 22 units in
three countries found a remarkably high incidence of AKI
in patients with septic shock [68]. Roughly 64% of these
patients developed early AKI as determined by the RIFLE
criteria. It also became obvious that delayed administra-
tion not only increases mortality as shown previously
[69], but also enhances the incidence of AKI. Patients
with AKI had a higher probability of having experienced
delayed administration of antibiotic therapy (6.0 vs. 4.3 h
in non-AKI).
In contrast to several studies trying to validate the
severity stages, the outcome stages have not been widely
evaluated. A retrospective analysis including 11,644 ICU
patients is the ﬁrst one that takes a deeper look into these
categories [70]. As reported by other studies, about 50%
of patients developed AKI, and 19% of those (i.e., 1,065
patients) required RRT. Seven hundred eighty-four
patients survived to hospital discharge, 97 (4.9%) patients
progressed to Loss and 282 patients remained in ESKD.
The main risk factors for developing ESKD were reported
to be elevated baseline creatinine and treatment with
intermittent haemodialysis.
Long-term outcome of AKI is still a ﬁeld of contro-
versy. A prospective multicentre study in France
including 205 patients with AKI treated with RRT
showed that 6 months after inclusion, only 62% of the
patients were still alive. Their SF-36 items were signiﬁ-
cantly decreased compared to the reference population,
especially with respect to physical items [71]. Two-thirds
of the survivors lived an autonomous life in their homes,
and 12% of the survivors still required RRT. Interestingly,
nearly all survivors (94%) would agree to undergo
intensive care management again.
Mannitol is an osmotic diuretic often administered for
treatment of acute cerebral oedema and is also recom-
mended as prevention against AKI in crush injury.
Despite this, little is known about its effects on renal
metabolism. By determining renal extraction of (51)
Cr-EDTA, it could be demonstrated [72] that in addition
the expected urine ﬂow, also the glomerular ﬁltration rate
(GFR) and ﬁltration fraction were increased by 20%.
Unfortunately, due to increased sodium load and con-
comitant tubular enhanced sodium reabsorption, renal
oxygen consumption is also increased. Combination of
mannitol with furosemide normalised oxygen consump-
tion of the kidney. Mannitol thus appears to be a good
example of the assumption that increasing GFR needs not
necessarily be a desired effect, because it may be asso-
ciated with increased oxygen consumption, putting the
kidney at risk of a demand supply imbalance.
Renal hemodynamics and hence function may be
signiﬁcantly inﬂuenced by intra-abdominal pressure. This
was demonstrated by the ﬁnding that paracentesis com-
bined with albumin substitution in patients with tense
ascites resulted in decreased renal resistive indexes
associated with a drop in intra-abdominal pressure from
20 to 12 mmHg [73]. This change was associated with a
nearly twofold increase in GFR from 5 to 9 ml/min
accompanied by increased urinary output.
Mild hypoxemia also appears to be a relevant factor
inﬂuencing renal hemodynamics. As shown in patients
with acute lung injury (ALI) requiring mechanical venti-
lation, an arbitrary reduction of FiO2 resulted in increased
renal resistive indices associated with increased GFR [74].
Urinary output and sodium excretion appeared unaltered.
The underlying mechanism as well clinical relevance of
these ﬁndings still needs to be further elucidated.
Acid base
Acid-base analysis
There has been a steady inﬂow of technical and physio-
logical reports during 2009. A highlight has been two
204reports on Stewart’s acid-base approach. Daniel Doberer
et al. [75] have pointed at limitations of this approach and
confusion in the interpretation of results. Gattinoni et al.
[76] have found Stewart’s approach useful also in the
clinical situation. An editorial by Andrew Davenport and
a number of letters to the editor have clearly demonstrated
the interest that has been stirred up by these papers [77–
79]. Not too far from this subject is a study by Zanella
et al. [80]. They showed in animal experiments how blood
acidiﬁcation at the inlet of membrane lung for extracor-
poreal CO2 removal (and oxygenation) improves the
extraction of CO2 from the passing blood. The rationale
for this test is that only a limited blood ﬂow is possible
through the membrane lung, 0.5 l/min, compared to the
much higher ventilation, 10 l/min. Means to improve CO2
elimination will thus be the only means of compensating
for the ﬂow limitation. Further testing may be needed in
clinical conditions.
Acid-base analysis has experienced considerable
advances since the introduction of the Steward approach
[81]. One study investigating the frequency of acid-base
disturbance in 175 critically ill patients demonstrated that,
by applying Stewart’s approach, additional diagnosis of
metabolic disorders was made possible in 33.7% of
patients with normal standard base excess [82], indicating
enhanced sensitivity by applying Stewart’s approach over
conventional analysis.
An investigation performed in patients after successful
CPR treated with therapeutic hypothermia showed that an
increased strong ion gap (SID) 12 h after ROSC may be
associated with unfavourable outcome [83].
Nutrition
In a large point prevalence study over nutrition practise in
107 ICUs across 37 countries around the world, Alberda
et al. [84] report an average caloric intake of 1,034 kcal/
day. When using the collected data as an observational
cohort study related to BMI, the authors demonstrated
that an increase of 1,000 kcal/day in energy intake would
be associated with a decrease in mortality when BMI\25
or when BMI [35. It was also reported that the caloric
intake was independent of BMI and that the the actual
caloric intake corresponded to approximately 60% of the
prescribed calories.
Several articles have addressed techniques to facilitate
administration of enteral nutrition. Using a capsule
monitored by a video camera, Rauch et al. [85] evaluated
small bowel transit time. No difference was found when
critically ill neurosurgical patients (n = 16) were com-
pared to healthy ambulatory subjects (n = 16), although a
larger variability in transit time was observed among the
critically ill patients. Holzinger et al. [86] report about a
self-advancing jejunal tube. Randomised ICU patients on
mechanical ventilation (n = 21 ? 21) had a lower suc-
cess rate of correct placement as compared to the
conventional endoscope-guided technique. Eventually
also all initially non-successful cases with the self-
advancing tube had correct placement by conventional
endoscopic guidance. No differences in outcome param-
eters were seen, and no predictor of success for the initial
use of the self-advancing jejunal tube was detected. To
determine if a simple aspiration test would be sufﬁcient to
detect the accuracy of oesophageal placement of a ﬁne-
bore feeding tube, Ward et al. [87] randomly inserted
tubes in the trachea and oesophagus in patients (n = 20)
undergoing elective surgery. A blinded investigator in-
sufﬂated and aspirated 10 ml of air and monitored the
effect on capnography. In the small series, the test accu-
rately differentiated between the two placements. Still the
authors emphasise the possibility of false-positive results.
The current literature demonstrates the provision of
early enteral nutrition (EN) having clinically important
beneﬁts in non-critically ill patients. Doig et al. [88]
present a systematic review on early EN in critically ill
patients using a meta-analysis of randomised controlled
trials. One criterion was the early application within 24 h
of ‘‘injury’’ or intensive care unit admission. The authors
were able to select six RCTs with a total of 234 patients.
Early EN was associated with a signiﬁcant reduction in
mortality by roughly 65%, and secondary pneumonia by
nearly 70%! Although these ﬁndings are robust and were
conﬁrmed by sensitivity analysis and a simulation study, a
major limitation of the presented analysis is the overall
low quality of the trials, as well as the low number of
included patients. Unfortunately, in current clinical
practice only 40 to 60% of patients who are eligible for
early EN still fail to receive early EN within 48 h of ICU
admission. Altogether, it must be concluded that this
impressive beneﬁt should be conﬁrmed by conducting
large multicentre trials enrolling critically ill patients.
Glycaemic control
The interest in tight glucose control and glucose moni-
toring har resulted in several articles. In a retrospective
analysis, Kreutziger et al. [89] demonstrated that admis-
sion blood glucose is an independent predictor of
mortality in polytraumatised patients, also when regres-
sion analysis controlled for age, gender and injury
severity. This is an original observation that needs to be
conﬁrmed. It may motivate consideration in the handling
of trauma cases. Cordingley et al. [90] investigated the
possible advantage with a computerised algorithm for the
insulin infusion in order to obtain blood glucose control.
In a feasibility study the comparison between two uni-
versity hospital ICUs demonstrated similar time-weighted
glucose averages when applying the algorithm advising
205insulin infusion rates. When standard care was used a
signiﬁcant difference in the time-weighted glucose aver-
ages occurred. Furthermore, the glucose sampling interval
decreased when the computerised algorithm was used.
Holzinger et al. [91] report the effect of noradrenaline
when a subcutaneous glucose monitoring system was
used. A multiple regression analysis was performed
demonstrating that noradrenaline dose, BMI, glucose
level and severity score had no inﬂuence on the accuracy
of the continuous glucose monitoring system in ICU
patients.
The multiple studies on the practical use of tight
glycaemic control (TGC) were in some ways more con-
fusing than helpful, since they used varying patient
populations and different protocols. In this context,
several studies tried to implement new technologies
called computerised decision-support systems (CDSS) to
establish supporting process management when using
TGC. Hence, the systematic review by Eslami et al. [92]
came at the right time. Using a predeﬁned algorithm, 11
systematic trials were selected. Although most studies
reported a positive effect on at least one quality indicator,
the protocols revealed a considerable diversity. The
authors conclude that, at present, it is impossible to deﬁne
the exact success factors. Although this may be disap-
pointing at the ﬁrst view, it is important to realise that
‘‘calling for technical support’’ using TGC is rather a view
into the future than a solution for the next years. Hence,
the physician is still dependent on sound protocols and
clinical assessment of the critically ill patient.
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